Pure Global
NCT06105229

Clinical Value of Plasma Humanin in Acute Kidney Injury

Guangdong Provincial People's Hospital·ClinicalTrials.govRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Kidney Injury
Study type
Observational
Sponsor & location
Primary sponsor
Guangdong Provincial People's Hospital
Location
Guangdong, China
Timeline & enrollment
Phase
N/A
Start date
Aug 01, 2022
End date
Jun 01, 2024
Enrollment
60 participants
Primary outcome

Humanin concentration,Serum creatinine concentration

Summary

The goal of this observational study is to assess the clinical value of humanin in acute
 kidney injury. The main questions it aims to answer are:whether Humanin can be a novel marker
 for predicting AKI Researchers will compare humanin concentration in healthy people to see if
 humanin can be a novel marker for predicting AKI

ICD-10 classifications
Injury of kidneyAcute renal failureAcute renal failure, unspecifiedOther acute renal failureAcute renal failure with tubular necrosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06105229
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06105229 through Pure Global AI's free database. This phase not specified trial is sponsored by Guangdong Provincial People's Hospital and is currently Recruiting. The study focuses on Acute Kidney Injury. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.